• +1-646-491-9876
    • +91-20-67278686

    Search

    Bacterial Vaginosis - Pipeline Review, H1 2017

    Bacterial Vaginosis - Pipeline Review, H1 2017

    • Report Code ID: RW0001689425
    • Category Healthcare
    • No. of Pages 47
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Vaginosis - Pipeline Review, H1 2017, provides an overview of the Bacterial Vaginosis (Infectious Disease) pipeline landscape.

    Bacterial vaginosis (BV), also known as vaginal bacteriosis is a type of vaginal inflammation caused by overgrowth of bacteria present in vagina. Symptoms include vaginal itching; burning during urination and vaginal discharge may become watery and thin. Treatment includes antibiotics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Bacterial Vaginosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bacterial Vaginosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Bacterial Vaginosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

    Bacterial Vaginosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Bacterial Vaginosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Bacterial Vaginosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Vaginosis (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Bacterial Vaginosis (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Bacterial Vaginosis - Overview
    Bacterial Vaginosis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Bacterial Vaginosis - Therapeutics Assessment
    Assessment by Route of Administration
    Assessment by Molecule Type
    Bacterial Vaginosis - Companies Involved in Therapeutics Development
    Evofem Inc
    Osel Inc
    Starpharma Holdings Ltd
    Symbiomix Therapeutics LLC
    Bacterial Vaginosis - Drug Profiles
    Amphora - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    astodrimer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    benzoyl peroxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LACTIN-V - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    secnidazole - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    subtilosin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TOL-463 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bacterial Vaginosis - Dormant Projects
    Bacterial Vaginosis - Discontinued Products
    Bacterial Vaginosis - Product Development Milestones
    Featured News & Press Releases
    Jan 19, 2017: Symbiomix Therapeutics Submits New Drug Application to US FDA for Solosec for the Treatment of BV
    Jan 12, 2017: VivaGel BV granted QIDP and Fast Track designation by US FDA
    Nov 07, 2016: Symbiomix Therapeutics to Present Data on Solosec (Secnidazole) Oral Granules at 2016 AAPS Annual Meeting and Exposition
    Oct 25, 2016: Symbiomix Therapeutics Data Presented on Clinician/Patient Perspectives of Bacterial Vaginosis at International Society for Quality of Life Research 23rd Annual Conference
    Oct 13, 2016: Enrolment complete for Phase 3 VivaGel BV-R program
    Aug 17, 2016: Evofem Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH
    Aug 17, 2016: Symbiomix Therapeutics Accelerates Commercial Launch Preparation for Solosec Following Presentation of Results from Second Pivotal Trial at IDSOG
    Jul 21, 2016: Osel Comments on New Study Showing Role of Vaginal Microbiome in Women Health
    May 26, 2016: Symbiomix Therapeutics Announces Positive Results from Phase 3 Trial of SYM-1219 for Bacterial Vaginosis, and Pre-NDA Meeting with FDA Supportive of 2016 NDA Filing
    May 11, 2016: Osel Lead Product LACTIN-V Enters Phase 2b Study to Prevent Recurrence of Bacterial Vaginosis
    Mar 31, 2016: Evofem Files IND for Evaluation of Prevention of Recurrence of Bacterial Vaginosis
    Jan 11, 2016: Evofem Holdings Announces Successful Completion of Pre-IND Meeting for Amphora
    Oct 14, 2015: Additional US Patent granted for VivaGel BV
    Sep 24, 2015: EU Marketing Approval Granted for VivaGel BV
    Sep 21, 2015: Symbiomix Therapeutics Presents Data at ICAAC/ICC Demonstrating Oral Pharmacokinetics of Lead Product SYM-1219 Administered With and Without Food
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Bacterial Vaginosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Bacterial Vaginosis - Pipeline by Evofem Inc, H1 2017
    Bacterial Vaginosis - Pipeline by Osel Inc, H1 2017
    Bacterial Vaginosis - Pipeline by Starpharma Holdings Ltd, H1 2017
    Bacterial Vaginosis - Pipeline by Symbiomix Therapeutics LLC, H1 2017
    Bacterial Vaginosis - Dormant Projects, H1 2017
    Bacterial Vaginosis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Bacterial Vaginosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Evofem Inc
    Osel Inc
    Starpharma Holdings Ltd
    Symbiomix Therapeutics LLC

    Request for Sample

    Report Url http://www.reportsweb.com//bacterial-vaginosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//bacterial-vaginosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//bacterial-vaginosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments